If you use a device running an Android version prior to 7.1.1, beginning January 11 your access from that device to this site and many others will be impaired. For details and solutions, see this topic.

Review: differences of patients with AD who are APOE4 carriers vs. those who are non-carriers

Insights and discussion from the cutting edge with reference to journal articles and other research papers.
BrianR
Senior Contributor
Senior Contributor
Posts: 223
Joined: Tue Oct 02, 2018 12:32 pm
Location: Southeastern Michigan

Review: differences of patients with AD who are APOE4 carriers vs. those who are non-carriers

Postby BrianR » Thu Nov 05, 2020 10:55 am

I thought this open access literature review was relatively readable (or at least, in my case, skimmable).
https://alzres.biomedcentral.com/articles/10.1186/s13195-020-00712-4

APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer’s disease: a systematic review.
Emrani, S., Arain, H.A., DeMarshall, C. et al.
Alz Res Therapy 12, 141 (2020).
DOI: 10.1186/s13195-020-00712-4

Abstract
Possession of the ε4 allele of apolipoprotein E (APOE) is the primary genetic risk factor for the sporadic form of Alzheimer’s disease (AD). While researchers have extensively characterized the impact that APOE ε4 (APOE4) has on the susceptibility of AD, far fewer studies have investigated the phenotypic differences of patients with AD who are APOE4 carriers vs. those who are non-carriers. In order to understand these differences, we performed a qualitative systematic literature review of the reported cognitive and pathological differences between APOE4-positive (APOE4+) vs. APOE4-negative (APOE4−) AD patients. The studies performed on this topic to date suggest that APOE4 is not only an important mediator of AD susceptibility, but that it likely confers specific phenotypic heterogeneity in AD presentation, as well. Specifically, APOE4+ AD patients appear to possess more tau accumulation and brain atrophy in the medial temporal lobe, resulting in greater memory impairment, compared to APOE4− AD patients. On the other hand, APOE4− AD patients appear to possess more tau accumulation and brain atrophy in the frontal and parietal lobes, resulting in greater impairment in executive function, visuospatial abilities, and language, compared to APOE4+ AD patients. Although more work is necessary to validate and interrogate these findings, these initial observations of pathological and cognitive heterogeneity between APOE4+ vs. APOE4− AD patients suggest that there is a fundamental divergence in AD manifestation related to APOE genotype, which may have important implications in regard to the therapeutic treatment of these two patient populations.

The authors dredge up many interesting little factoids/assertions regarding differing expressions of AD in APOE4 patients.

Brenita
Contributor
Contributor
Posts: 7
Joined: Mon Dec 04, 2017 9:42 am
Contact:

Re: Review: differences of patients with AD who are APOE4 carriers vs. those who are non-carriers

Postby Brenita » Sat Nov 21, 2020 5:47 pm

Interesting.
Brenita
APoe 3/4


Return to “Science and Research”

Who is online

Users browsing this forum: No registered users and 11 guests